Drug Approval | February 20, 2022
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Subscribe To Our Newsletter & Stay Updated
